Aimmune Therapeutics, Inc. (NASDAQ: AIMT) Starts Presentation at 30th Annual ROTH Conference
Aimmune Therapeutics (NASDAQ: AIMT) is a clinical-stage biopharmaceutical company developing treatments for potentially life-threatening food allergies. The company’s Characterized Oral Desensitization ImmunoTherapy (CODIT™) approach is intended to achieve meaningful levels of protection by desensitizing patients with defined, precise amounts of key allergens. Aimmune’s first investigational biologic product using CODIT™, AR101 for the treatment of peanut allergy, has received the FDA’s Breakthrough Therapy Designation for the desensitization of peanut-allergic patients 4–17 years of age and is currently being evaluated in Phase 3 clinical trials. For more information, visit the company’s website at www.aimmune.com. About NetworkNewsWire NetworkNewsWire (NNW) is a financial news…







